China’s Orthopedics Battle: Stryker Jumps In To Buy Trauson
This article was originally published in PharmAsia News
Executive Summary
China’s red hot orthopedics market sees another major deal, with Stryker offering to acquire Trauson Holdings for $764 million, a 45% premium over the firm’s last closing price.
In the third major acquisition by a multinational in China’s orthopedic space, Stryker Corp. announced Jan. 17 that it has offered to buy Trauson Holdings, the leading trauma manufacturer in China, for $764 million in cash. Stryker’s offer of HK $7.50 per ordinary share is a 45% premium over Trauson’s last closing price. The deal is an opportunity for Stryker to increase its presence in China and to compete in other emerging markets using a well-established brand for the value segment, according to the company. Stryker’s move follows recent acquisitions in China’s orthopedics space by Medtronic Inc. and Zimmer Holdings Inc. (Click here for more
.)
“Stryker Offers $764 Million for Trauson to Expand in China” – Bloomberg Businessweek(1/17/2013)